Get the Latest Investment Ideas Delivered Straight to Your Inbox. Subscribe


Biotech's Flu Vaccine Shows 'Superiority to Market Leader' in Data
Research Report

Share on Stocktwits


Study findings that differentiate this product from competitors were reviewed in a Ladenburg Thalmann research report.


In a Jan. 10 research note, analyst Michael Higgins with Ladenburg Thalmann reported that Novavax Inc. (NVAX:NASDAQ) just released updated Phase 2 data that show NanoFlu's "superiority to the market leader" Fluzone HD in several H3N2 strains that cause the most deaths.

In the trial, Novavax's eggless flu vaccine was assessed against two comparators, including Fluzone HD, in adults aged 65 and older. Newly released results were from day 28 of the study.

Higgins highlighted the significant advantages of NanoFlu. One, a finding that was revealed in the newly released data, is its efficacy against "drifted strains" that can be deadly, as well as against homologous strains.

"Efficacy against drifted strains is likely the most difficult to get and is the best indication of how a vaccine will handle the annual variability that stumps so many flu vaccines," Higgins added. "The mismatching between the recommended strains and the actual flu strains produces the sharp year-to-year differences in flu deaths."

Another benefit of NanoFlu is it eliminates the potential for "virus egg adaptations" through its egg-free manufacturing of the product, the analyst stated.

Higgins concluded that "based on Phase 2 results, we believe that NanoFlu could become the new standard of care for older adults."

Next for NanoFlu are further data releases from the Phase 2 study. Also, Novavax will meet with the FDA, likely in April, to discuss the Phase 2 study results, a Phase 3 trial design and the potential for faster approval of the vaccine. An accelerated pathway would mean the Phase 3 study could launch in Q4/19 and end in early Q1/20. "We believe such a path is possible," indicated Higgins.

Ladenburg Thalmann has a Buy rating and a $3.50 per share price target on Novavax, whose stock is currently trading at around $2.17 per share.


1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.

Disclosures from Ladenburg Thalmann, Novavax, Inc., January 10, 2019

ANALYST CERTIFICATION: I, Michael Higgins, attest that the views expressed in this research report accurately reflect my personal views about the subject security and issuer. Furthermore, no part of my compensation was, is, or will be directly or indirectly related to the specific recommendation or views expressed in this research report, provided, however, that:

The research analyst primarily responsible for the preparation of this research report has or will receive compensation based upon various factors, including the volume of trading at the firm in the subject security, as well as the firm’s total revenues, a portion of which is generated by investment banking activities.

Ladenburg Thalmann & Co. Inc. makes a market in Novavax, Inc.
Ladenburg Thalmann & Co. Inc. has managed or co-managed a public offering for Novavax, Inc. within the past 12 months.
Ladenburg Thalmann & Co. Inc. intends to seek compensation for investment banking and/or advisory services from Novavax, Inc. within the next 3 months.
Ladenburg Thalmann & Co. Inc received compensation for investment banking services from Novavax, Inc. within the past 12 months.
Ladenburg Thalmann & Co. Inc had an investment banking relationship with Novavax, Inc. within the last 12 months.

Want to read more about Biotechnology / Pharmaceuticals investment ideas?
Get Our Streetwise Reports Newsletter Free and be the first to know!

A valid email address is required to subscribe